NASDAQ:IOVA News 3 November 2025 - 23 December 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back on traders’ radar heading into Dec. 23, 2025, after a sharp move higher to $2.78 at the Dec. 22 close (up 12.10% on the day) and an early pre-market indication around $2.80. StockAnalysis That bounce matters because Iovance has become the kind of stock where small news can hit like a cymbal crash—and not just because it’s biotech. With short interest around one-third of the float (by recent exchange reporting), any new analyst note, operational update, or sentiment shift can amplify price swings. MarketBeat Below is a detailed roundup of the current news,

December 18, 2025 — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to reignite the “is this finally a bottom?” debate around one of biotech’s most volatile commercial launches. According to Investing.com’s recent trading history, IOVA jumped 12% on Wednesday, December 17, closing at $2.52 on 23.27 million shares after already rising on December 16. Investing.com As of December 18, the stock continued to trade around $2.52, with a recent 52-week range of

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel (brand name Amtagvi) earned FDA approval in 2024 as the first-ever TIL therapy (and the first cellular therapy for any solid tumor)cancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapies (e.g.